LEADER 02208nam  2200481   450 
001 9910137668803321
005 20221010201921.0
010   $a953-51-4363-8
035   $a(CKB)3230000000077138
035   $a(NjHacI)993230000000077138
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/61066
035   $a(MiAaPQ)EBC30390164
035   $a(Au-PeEL)EBL30390164
035   $a(EXLCZ)993230000000077138
100   $a20221010d2012      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aToxicity and Drug Testing /$fedited by Bill Acree
205   $a1st ed.
210   $cIntechOpen$d2012
210  1$aCroatia :$cIntechOpen,$d2012.
215   $a1 online resource (530 pages)
311   $a953-51-0004-1 
330   $aModern drug design and testing involves experimental in vivo and in vitro measurement of the drug candidate's ADMET (adsorption, distribution, metabolism, elimination and toxicity) properties in the early stages of drug discovery. Only a small percentage of the proposed drug candidates receive government approval and reach the market place. Unfavorable pharmacokinetic properties, poor bioavailability and efficacy, low solubility, adverse side effects and toxicity concerns account for many of the drug failures encountered in the pharmaceutical industry. Authors from several countries have contributed chapters detailing regulatory policies, pharmaceutical concerns and clinical practices in their respective countries with the expectation that the open exchange of scientific results and ideas presented in this book will lead to improved pharmaceutical products.
606   $aToxicology
610   $aToxicology
610   $aToxicology and Pharmaceutical Science
610   $aToxinology
610   $aPharmacology
610   $aHealth Sciences
615  0$aToxicology.
676   $a615.9
700   $aWilliam Acree$4auth$01365335
702   $aAcree$b Bill
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910137668803321
996   $aToxicity and Drug Testing$93387141
997   $aUNINA